Pharma Glass Tubing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The pharma glass tubing market size in 2026 is estimated at USD 15.33 billion, growing from 2025 value of USD 14.43 billion with 2031 projections showing USD 20.79 billion, growing at 6.27% CAGR over 2026-2031. This report is Segmented by Application (Vials, Ampoules, Cartridges, and More), Glass Type (Type I Neutral Borosilicate 5. 0, Type II Soda-Lime Treated, and More), Forming Process (Tubular, Molded, Ready-To-Use RTU Tubing), End User (Pharmaceutical Manufacturers, Generic Drug Manufacturers, and More), Glass Color (Clear, and Amber), and Geography. The Market Forecasts are Provided in Terms of Value (USD)

Global Pharma Glass Tubing Market Trends and Insights

Injectable Biologics Drive Unprecedented Demand for Sterile Glass Containers

A wave of monoclonal antibodies, GLP-1 drugs, and mRNA vaccines is driving unprecedented volume requirements for Type I borosilicate vials and syringes. Stevanato Group reported 22.1% revenue growth in Q1 2025, anchored by its Vertiva 10 mL delivery system purpose-built for GLP-1 formulations. Investments mirror demand: Nipro Corporation allocated USD 398 million (EUR 366 million) to a North Carolina plant slated to add 2 billion vials annually from late-2025. Cell and gene therapies, which require ultra-low extractables, further entrench glass as the de-risked container choice. Contract Development and Manufacturing Organizations (CDMOs) translate these biologics pipelines into bulk tubing orders, ensuring sustained growth for the pharma glass tubing market.

Regulatory Mandates Solidify Type I Borosilicate Glass Supremacy

The FDA’s 2024 container-closure guidance codifies risk-based assessments that heavily favor borosilicate’s inert profile. Parallel alignment by the European Medicines Agency and China’s updated YY 1001-2024 syringe standard solidifies a global norm. Drug developers view regulatory acceptance as non-negotiable, channeling purchases toward Type I tubing even when costlier than soda-lime variants. This harmonized stance raises entry barriers for polymers while anchoring long-run demand across the pharma glass tubing market.

COP/COPP Polymers Challenge Glass in Cost-Sensitive Applications

Cyclic olefin polymer and cyclic olefin copolymer containers attract cost-sensitive generics makers with shatter resistance and weight savings. Yet polymer uptake stalls in biologics owing to immature long-term stability data compared with glass. Regulatory conservatism compounds polymer hurdles, sustaining Type I usage even as polymer vendors sharpen value propositions on total cost of ownership. In emerging markets prioritizing price, polymers may erode share temporarily, but high-value therapies continue to secure the pharma glass tubing market trajectory.

Other drivers and restraints analyzed in the detailed report include:

• Circular Economy Initiatives Position Glass as Sustainable Packaging Solution
• Near-Site Manufacturing Drives Domestic Glass Tubing Demand
• Raw Material Cost Volatility Pressures Glass Manufacturing Economics

Segment Analysis

Global revenue data confirm that vials captured 40.76% of the pharma glass tubing market in 2025, underpinned by their versatility for freeze-drying, multi-dose vaccines, and sensitive biologics. Vials also represent the single largest slice of the pharma glass tubing market size for 2025, encouraged by automation-friendly geometry. Technology advances such as Nipro’s D2F vials add drop-impact resistance that lowers waste during high-speed filling. Continued investment by CDMOs extends vial order books well into the forecast window.

Syringes, however, log the fastest growth trajectory at 7.31% CAGR owing to self-administration trends and combination-product approvals. The Vertiva platform illustrates how larger-volume glass syringes address viscosity challenges in GLP-1 drugs, thereby expanding use-cases beyond traditional 1 mL formats. Regulatory bias toward glass for biologics cements the momentum. Together, vials and syringes constitute twin pillars that reinforce the expansion of the pharma glass tubing market.

Type I borosilicate retained a commanding 63.54% share of the pharma glass tubing market size in 2025, reflecting decades of regulatory trust. Numerous FDA filings cite borosilicate containers as the reference standard, preserving installed filling infrastructure. Aluminosilicate tubing, though still niche, is growing at 8.1% CAGR because of its higher mechanical strength that permits thinner walls and lower weight, yielding logistics savings. Valor-grade variants meet Pharma 3407 protocols, positioning aluminosilicate as a premium alternative for ultra-high-value injectables, thereby diversifying material options within the pharma glass tubing market.

Complete Report Scope:

• By Application
  • Vials
  • Ampoules
  • Cartridges
  • Syringes
  • Other Applications
• By Glass Type
  • Type I (Neutral Borosilicate 5.0)
  • Type II (Soda-Lime Treated)
  • Type III (Soda-Lime)
  • Aluminosilicate / Valor-type
• By Forming Process
  • Tubular
  • Molded
  • Ready-to-Use (RTU) Tubing
• By End User
  • Pharmaceutical Manufacturers
  • Generic Drug Manufacturers
  • Contract Development and Manufacturing Organizations (CDMOs)
  • Research and Academic Laboratories
• By Glass Color
  • Clear
  • Amber
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Chile
    • Rest of South America
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • Middle East and Africa
    • Middle East
      • Saudi Arabia
      • United Arab Emirates
      • Turkey
      • Rest of Middle East
    • Africa
      • South Africa
      • Nigeria
      • Kenya
      • Rest of Africa

Geography Analysis

North America contributed 38.96% of global 2025 revenues, sustained by robust biologics pipelines, stringent FDA standards, and expanding domestic production footprints like Nipro’s Carolinas complex. The region benefits from public-private investment initiatives aimed at supply-chain resilience, translating into multi-year sourcing contracts that secure the pharma glass tubing market.

Europe follows closely, leveraging century-old glassmaking clusters and leadership in circular-economy regulations that favor endlessly recyclable packaging. Capacity expansions by SCHOTT and SGD Pharma’s recycled-content launch showcase the region’s dual focus on volume and sustainability. Yet EU carbon pricing raises cost pressure, compelling furnace electrification projects and alliances to share decarbonization know-how.

Asia-Pacific is the fastest mover at a 8.79% CAGR, driven by China’s biopharmaceutical scale-up and regulatory convergence to ICH norms. Shandong Pharmaceutical Glass’s double-digit revenue jump in H1 2024 depicts strong domestic uptake. ASEAN harmonization promises streamlined cross-border approvals, boosting regional trade in pharma glass tubing. Collectively, these dynamics feed a geographically diversified and resilient pharma glass tubing market.

List of Companies Covered in this Report:

• SCHOTT AG
• Corning Incorporated
• Nipro Corporation
• Nippon Electric Glass Co., Ltd.
• Gerresheimer AG
• Stevanato Group S.p.A.
• SGD Pharma SAS
• Shandong Pharmaceutical Glass Co., Ltd.
• Cangzhou Four-Star Glass Co., Ltd.
• Shandong Linuo Technical Glass Co., Ltd.
• Chongqing Zhengchuan Pharmaceutical Packaging Co., Ltd.
• Triumph JunHeng Pharmaceutical Glass Co., Ltd.
• DWK Life Sciences GmbH
• Aimer Products Limited
• Puyang New Harmony Industrial Development Co., Ltd.
• Jinan YoulYY Industrial Co., Ltd.
• Jinan Snail International Co., Ltd.
• West Pharmaceutical Services, Inc.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support